Cilgavimab / tixagevimab Pregnancy and Breastfeeding Warnings
Brand names: Evusheld
Medically reviewed by Drugs.com. Last updated on Feb 7, 2023.
Cilgavimab / tixagevimab Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
Comments:
-Insufficient data are available on use of this product in pregnant women; no nonclinical reproductive toxicity studies have been performed with the active components.
-Human immunoglobulin G1 (IgG1) antibodies cross the placental barrier; the active components have the potential to be transferred from the mother to the developing fetus.
Animal studies have not been reported. In a tissue cross reactivity study with the active components using human fetal tissues, no binding of clinical concern was detected. There are no controlled data in human pregnancy.
Cilgavimab / tixagevimab Breastfeeding Warnings
Benefit should outweigh risk.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments:
-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this product.
-The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this product or the mother's underlying condition should be considered.
See also
References for pregnancy information
- (2023) "Product Information. Evusheld (cilgavimab-tixagevimab)." AstraZeneca Canada Inc
References for breastfeeding information
- (2023) "Product Information. Evusheld (cilgavimab-tixagevimab)." AstraZeneca Canada Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.